Lung Cancer Flashcards

1
Q

tumor growth and clinical presentation

A

for a single malignant cell with a doubling itme of 3-4 months to grow to a 1 cm nodule, it would take about 7-10 years

therefore, 75% of the life history of the cancer is in the undetectable stage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

major pathologic cell types of lung cancer

A

small cell carcinoma, adenocarcinoma, squamous cell carcinoma, and large cell carcinoma

the latter three have overlapping clinical behaviors and are often grouped into non-small cell lung cancer (NSCLC) - 80% of all lung cancers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

general characteristics of small cell lung cancer

A

strong relationship to cigarette smoking

only about 1% occur in nonsmokers

no known preinvasive phase or carcinoma in situ

the most aggressive of lung tumors, metastasize weidely, and are virtually incurable by surgical means

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

genes frequently mutated in small cell lung cancer

A

p53 and RB1 tumor suppressor genes

high levels of anti-apoptotic protein BCL2

low frequency of expression of the pro-apoptotic protien BAX

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

presentation of small cell lung cancer

A

central mass and lymphadenopathy

highly sensitive to chemotherapy and radiation initially - patient starts to deteriorate after 6-9 months

limited stage - lymph nodes and mass encopassable in one radiographic port

extensive stage - everything else

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

treatment for SCLC

A

LS (1/3) -> radiation/chemotherapy

ES (2/3) -> chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

T component of TNM staging

A

The ‘T’ component reflects the tumor size and invasiveness. T values range from 0 to 4; T0 indicates no evidence of primary tumor, while T4 indicates extensive extrapulmonary extension.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

N component of TNM staging

A

The ‘N’ component indicates the absence or presence and extent of regional lymph node metastasis. N values range from 0 to 3; N0 indicates no regional lymph node metastasis, while N3 indicates metastasis to contralateral hilar and ipsilateral and contralateral supraclavicular/scalene lymph nodes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

M component of TNM staging

A

The ‘M’ component defines the absence or presence of tumor spread to distant lymph nodes or organ sites. M values range from 0 to 1; M0 disease indicates no distant metastasis, while M1 indicates the presence of distant metastasis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

strategies for screening lung cancer

A

chest x-rays

sputum analysis

CT scans

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

advantages of lung cancer CT screening

A

increases detection of early-stage lung cancer

improves lung-cancer specific and overall mortality in a high risk population

most realistic strategy or improving lung cancer mortality

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

disadvantages of lung cancer CT screening

A

high positive rate

benefits may not extrapolate to lower risk populations

long-term risk of repetitive radiation exposure

cost

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Stage I and treatment

A

tumor of any size is found only in the lung

treatment - surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Stage II and treatment

A

tumor has spread to lymph nodes associated with the lung

surgery/chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Stage IIIA and treatment

A

tumor has spread to the lymph nodes in the tracheal area, including chest awall and diaphragm

combination of surgery, radiation, and chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Stage IIIB and treatment

A

tumor has spread to the lymph nodes on the opposite lung or in the neck

combination of chemotherapy and radiation

17
Q

Stage IV and treatment

A

tumor has spread beyond the chest

chemotharapy and/or palliative (maintenance) care

18
Q

criteria for surgery in stage I/II NSCLC

A

predicted FEV1 after pneumonectomy is 1.2L

patient is not hypercapnic

patient does not have cor pulmonale

19
Q

adjuvant therapy

A

treatment to keep cancer from returning

patients with resectable disease are the only group likely to be cured of their cancer

20
Q

pulmonary manifestations of lung cancer

A

cough from endobronchial erosion and irritation

dyspnea

chest pain

hemoptysis

postobstructive pneumonia or pneumonitis

large tumors may cavitate and present as lung abscesses

21
Q

pulmonary manifestatiosn of centrall located lung tumors

A

stridor

wheezing

hemoptysis

dyspnea

chest pain in the central location

22
Q

manifestations of intrathoracic disease

A

hoarseness from invasion of the recurrent laryngeal nerve and resultant vocal cord paralysis

dysphagia as a result of esophageal compression

superior vena cava syndrome

shoulder arm pain from superior sulcus due to local extension of a tumor in the apex of the lung that compresses the nerves

ipsilateral Horner syndrome

23
Q

superior vena cava syndrome

A

characterized by plethoric apperance, distension of the venous drainage of the arm and neck, edema of the face, neck and arms

collateral venous drainage may also form

dilated veins over anterior chest

24
Q

ipsilateral Horner syndrome

A

characterized by ptosis, meiosis, and anhydrosis due to paravertebral extension and sympathetic nerve involvement of the tumors

25
paraneoplastic syndromes as a result of lung cancer
cytokin-mediated responses to antigens from the intrathroacic lung tumor rather than the result of distant spread of cancer manifestations of clubbing, hypertrophic osteoarthropathy, and neurologic and hormonaal abnormalities
26
mainfestations of extrathoracic disease in lung cancer
most common are anorexia, weight loss, and fatigue bone pain accompanies mets tot he bone CNS involvement is low with cancer that has not spread to the lymph patients with signs of mediastinal or distant involvement, the risk of occult brain mets increases the adrenal gland is the most frequent site of distant mets of lung cancer
27
treatment paradigms for advanced NSCLC
2-drug platinum-based chemotherapy improves survival and quality of life in patients iwht good PS chemo is better than supportive care 2 drugs better than 1 drug 3 drugs not better than 2 drugs treatment should be limited to 4-6 cycles of chemo
28
hallmarks of cancer
self-sufficiency in growth signals insensitiveity to antigrowth signals tissue invasion and metastasis limitless replicative potential sustained angiogenesis evading apoptosis
29
targeted therapy in oncology
goal is to identify anti-tumor agents that target tumor-specific molecules and spare normal cells
30
ideal targeted therapy drug target
drives tumor growth turns on key mechanisms of cancer progression reversible by inhibition dispensable in normal cells target is measureable in tumor tissue used for diagnosis
31
Erlotinib
quinazolinamine-derived small-molecule inhibitor of the EGFR kinase inhibits the intracellular phosphorylation of the tyrosine kinase associated with EGFR the mechanism of clinical antitumor action of erlotinib is not fully characterized
32
EGFR
epidermal growth factor receptor, also called ErbB1 a transmembrane receptor tyrosine kinase of human epidermal growth factor receptor (HER) dimerizes to become activated after ligand binding activation contributes to cell division, migration, adhesion, and survival
33
Gefitinib
similar to erlotinib EGFR tyrosine kinase inhibitor
34
EML4-ALK fusion mutation
associated with adenocarcinoma histology fusion results in activation of tyrosine kinase that enhances cell proliferation and survival about 25% of all lung cancers in never-smokers
35
crizotinib
small molecule tyrosine inhibitor approved in 2011 for treating tumors that possess the EML4-ALK fusion protein
36
bevacizumab
a monoclonal antibody to vascular endothelial growth factor (VEGF) neutralization can inhibit tumor vascularization and block tumor growth useful for patients with non-squamous NSCLC
37
Pancoast's Tumor
superior sulcus tumor usually squamous cell usually initial symptoms are pain, sometimes upper extremity weakness invasion of brachial plexus, 40%
38
Lambert-Eaton Syndrome
a syndrome that falls under paraneoplastic syndrome similar to myasthenia gravis clinically proximal muscle weakness and gait disturbance strength increased with exercise characterized by antibodies directed against voltage-gated calcium channel and interfere with normal calcium flux necessary for release of ACh
39
hypertrophic osteoarhopathy
thoracic malignancy is the most common cause pain is often present more common with adenocarcinoma clubbing is often the first clue